TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024
Helsinki, Finland – 10 April 2024: TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024.
